Novavax Inc (NVAX)

Name: Novavax Inc (NVAX) annual fundamentals
Creator: TickerFacts
License: https://creativecommons.org/publicdomain/zero/1.0/

Build a valuation ↗↓ Download CSV

SEC name NOVAVAX INC · CIK 0001000694 · Nasdaq · Biological Products, (No Diagnostic Substances)

Sector Manufacturing
Incorporated DE
Fiscal year ends Dec 31

For the year ended 2025-12-31, Novavax Inc reported revenue of $1.12B. Revenue grew 64.7% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $413.80M.

Key ratios (year ended 2025-12-31)

93.5%

Gross margin (computed)

40.3%

Operating margin

39.2%

Net margin

64.7%

Revenue growth (YoY)

Computed by TickerFacts from revenue minus cost of revenue. This may differ from the issuer's reported gross profit or margin; check the revenue and cost definitions.

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 8-K (current report) · 2026-08-06

Headquarters locality: Gaithersburg · View on map

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period ended	TTM to 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Revenue	$413.80M	$1.12B	$682.16M	$983.71M	$1.98B	$1.15B	$475.60M	$18.66M	$34.29M	$31.18M	$15.35M
Cost of Revenue	$88.54M	$73.04M	$202.74M	$343.77M	$902.64M	$0	$0	n/a	n/a	n/a	n/a
Gross Profit (computed)	$325.25M	$1.05B	$479.42M	$639.94M	$1.08B	n/a	n/a	n/a	n/a	n/a	n/a
R&D Expense	$340.31M	$342.32M	$391.17M	$737.50M	$1.24B	$2.53B	$747.03M	$113.84M	$173.80M	$168.44M	$237.94M
Operating Income	-$234.12M	$452.80M	-$248.93M	-$566.51M	-$644.74M	-$1.69B	-$416.72M	-$120.58M	-$173.92M	-$171.71M	-$269.11M
Depreciation & Amortization	$17.83M	$27.61M	$48.50M	$41.23M	$29.05M	$12.66M	$4.88M	$5.68M	$8.16M	$9.82M	$8.51M
EBITDA	-$216.30M	$480.41M	-$200.44M	-$525.29M	-$615.68M	-$1.67B	-$411.83M	-$114.91M	-$165.76M	-$161.89M	-$260.61M
Net Income	-$247.73M	$440.30M	-$187.50M	-$545.06M	-$657.94M	-$1.74B	-$418.26M	-$132.69M	-$184.75M	-$183.77M	-$279.97M
EPS (Diluted)	n/a	$2.58	-$1.23	-$5.41	-$8.42	-$23.44	-$7.27	-$5.51	n/a	n/a	n/a
Total Assets	$955.58M	$1.18B	$1.56B	$1.80B	$2.26B	$2.58B	$1.58B	$172.96M	$207.98M	$302.49M	$394.30M
Total Liabilities	$1.15B	$1.30B	$2.18B	$2.51B	$2.89B	$2.93B	$955.27M	$358.97M	$375.91M	$404.23M	$399.85M
Shareholders' Equity	-$190.71M	-$127.75M	-$623.84M	-$716.93M	-$634.08M	-$351.67M	$627.21M	-$186.02M	-$167.94M	-$101.73M	-$5.55M
Cash & Equivalents	$191.46M	$240.63M	$530.23M	$568.50M	$1.34B	$1.52B	$553.40M	$78.82M	$70.15M	$106.31M	$144.35M
Operating Cash Flow	-$36.90M	-$244.63M	-$87.26M	-$713.97M	-$415.94M	$322.95M	-$42.54M	-$136.62M	-$184.82M	-$144.48M	-$258.77M
Capital Expenditures	n/a	n/a	n/a	n/a	n/a	$57.49M	$54.62M	$1.86M	$1.37M	$4.19M	$18.20M
Free Cash Flow	n/a	n/a	n/a	n/a	n/a	$265.46M	-$97.16M	-$138.48M	-$186.20M	-$148.66M	-$276.97M
Shares Outstanding	164.82M	162.58M	160.42M	139.51M	86.04M	75.84M	70.95M	32.35M	19.22M	323.23M	271.25M
Weighted Average Diluted Shares	n/a	173.10M	152.19M	100.77M	78.18M	74.40M	57.55M	24.10M	n/a	n/a	n/a
EPS (Basic)	n/a	$2.72	-$1.23	-$5.41	-$8.42	-$23.44	-$7.27	-$5.51	n/a	n/a	n/a

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView